A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores

Takeo Fujii1,2,3,4 · Hiroko Masuda5 · Yee Chung Cheng6 · Fei Yang7 · Aysegul A. Sahin8 · Yasuto Naoi9 · Yuki Matsunaga2 · Akshara Raghavendra1 · Arup Kumar Sinha1 · Jose Rodrigo Espinosa Fernandez1 · Anjali James1 · Keisuke Yamagishi10 · Tomoko Matsushima10 · Robert Schuetz4 · Debu Tripathy1 · Sachiy0 Tada9 · Rubie S. Jackson11 · Shinzaburo Noguchi9,12 · Seigo Nakamura5 · Jared D. Acoba3,4 · Naoto T. Ueno1,2

Received: 26 September 2020 / Accepted: 28 May 2021 / Published online: 15 June 2021 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021

Abstract

Purpose A subset of patients with intermediate 21-gene signature assay recurrence score may benefit from adjuvant chemoendocrine therapy, but a predictive strategy is needed to identify such patients. The 95-gene signature assay was tested to stratify patients with intermediate RS into high (95GC-H) and low (95GC-L) groups that were associated with invasive recurrence risk.

Methods Patients with ER-positive, HER2-negative, node-negative breast cancer and RS 11–25 who underwent definitive surgery and adjuvant endocrine therapy without any cytotoxic agents were included. RNA was extracted from archived formalin-fixed, paraffin-embedded samples, and 95-gene signature was calculated.

Results 206 patients had RS of 11–25 (95GC-L, N = 163; 95GC-H, N = 43). In Cox proportional hazards model, 95GC-H was significantly associated with shorter time to recurrence than was 95GC-L (HR 5.94; 95%CI 1.81–19.53; P = 0.005). The correlation between 95-gene signature and 21-gene signature assay scores was not strong (correlation coefficient r = 0.27), which might suggest that 95-gene signature reflects biological characteristics differing from what 21-gene signature shows.

Conclusions The 95-gene signature stratifies patients with ER-positive, HER2-negative, node-negative invasive breast cancer and intermediate RS of 11–25 into high and low groups that are associated with recurrence risk of invasive disease. Further retrospective analysis in the prospectively accrued TAILORx population is warranted to confirm that 95-gene signature can identify patients who would benefit from adjuvant chemoendocrine therapy.

Keywords Breast cancer · 21-gene signature assay · 95-gene signature assay · Estrogen receptor-positive · Recurrence Score

Introduction

The 21-gene signature assay (or 21-gene recurrence assay, Oncotype DX®, Exact Sciences Corporation, Madison, WI) measures 21 genes by quantitative reverse transcriptase-PCR using formalin-fixed, paraffin-embedded (FFPE) tissues to determine a Recurrence Score (RS). This RS estimates the likelihood of distant metastasis at 10 years from the date of diagnosis and conventionally stratifies patients into three risk groups: low (RS < 18), intermediate (RS 18–30), and high (RS > 30) [1]. Consideration of 21-gene signature assay RS scores has been incorporated into guidelines from the American Society of Clinical Oncology, National Comprehensive Cancer Network, and European Society of Medical Oncology [2–4]. Currently, chemotherapy in addition to endocrine therapy is strongly recommended for patients with high RS [2, 3]. The benefit of adding chemotherapy to endocrine therapy is thought to be minimal in those with low RS, a practice supported by results of TAILORx trial: For patients with RS of 0–10, the 5-year invasive disease-free survival rate was 93.8% (95% confidence interval [CI] 92.4–94.9), and the 5-year distant recurrence-free survival rate was 99.3% (95% CI 98.7–99.6) [5]. Further, the
TAILORx trial demonstrated that adjuvant endocrine and chemoendocrine therapies had similar efficacy in patients with hormone receptor-positive, HER2-negative, node-negative breast cancer with RS of 11–25 (hazard ratio [HR] of invasive disease-free survival after endocrine vs. chemoendocrine therapies, 1.08; 95% CI 0.94–1.24; \( P = 0.26 \)) [6]. However, in that study, the estimated invasive disease-free survival rate at 9 years in patients with RS of 11–25 treated with endocrine therapy was 83.3% ± 0.9% and approximately 17% of intermediate RS patients may have an event within 9 years. This fact suggests that there must be a subset of patients with intermediate RS of 11–25 who may benefit from adjuvant chemoendocrine therapy. A predictive strategy to identify such patients is an unmet need. The ability to predict chemoendocrine therapy benefit in the setting of intermediate RS is limited particularly in postmenopausal or older women [7].

The 95-gene-based signature (95GC, Curebest™ 95GC Breast, Sysmex Corporation, Kobe, Japan) was developed using a DNA microarray to predict the risk of recurrence of ER-positive, node-negative primary breast cancer in 549 patients who have undergone definitive surgery and adjuvant endocrine therapy from the public datasets (GSE2034, GSE2990, GSE4922, GSE6532, GSE7390, GSE9195) [8]. The 95 genes were mathematically selected from approximately 20,000 human genes without human bias, which is distinct from 21-gene signature and 95 genes selected are mutually exclusive of the 21 genes. Given this fact, 95-gene signature is able to observe the biological characteristics different from 21-gene signature. Whereas 21-gene signature assay stratifies patients into three risk categories, 95-gene signature stratifies patients into two risk categories: 95GC-Low (95GC-L) and 95GC-High (95GC-H). In a 105-patient cohort, the 5-year recurrence-free survival (RFS) rates were 96.7% for 95GC-L and 58.1% for 95GC-H (\( P < 0.001 \)) [8]. In an independent 75-patient cohort, the 5-year RFS rates were 96.5% for 95GC-L and 79.1% for 95GC-H (\( P = 0.0017 \)) [9]. Another retrospective study with a large cohort compared 95-gene signature and the 21-gene classifier of Recurrence Online, which is comparable to 21-gene signature assay [10, 11].

Among the 459 patients in that study, 174 (37.9%) were classified into 95GC-H and 285 patients (62.1%) were classified into 95GC-L. RFS was significantly better in the 95GC-L group than in the 95GC-H group (log rank \( P = 5.5 \times 10^{-10} \)). Based on the 21-gene classifier, 81 of the 459 patients (17.6%) had intermediate scores. Those 81 patients were stratified using 95GC: 38 patients (46.9%) as 95GC-L and 43 patients (53.1%) as 95GC-H. RFS was significantly better in the 95GC-L group than in the 95GC-H group (log rank \( P = 0.002 \)). Those results suggest that 95GC might have utility for classifying patients with intermediate 21-gene signature assay RS into high- and low-risk groups. However, because the study used Recurrence Online to determine the estimated recurrence possibility by 21-gene signature, there is a need for validation using 21-gene signature assay and 95-gene signature in an independent patient cohort.

Our hypothesis is that the 95-gene signature can stratify patients with ER-positive, HER2-negative, node-negative, invasive breast cancer and an intermediate 21-gene signature assay RS of 11–25 into binary recurrence risk categories.

Methods

Study population

This retrospective chart review with linked tissue analysis was approved by the Institutional Review Boards at the five participating institutions in the USA and Japan: The University of Texas MD Anderson Cancer Center (protocol number: PA15-0905), University of Hawai’i Cancer Center (protocol number: RA-2017-021), Medical College of Wisconsin (protocol number: PRO00029366), Anne Arundel Medical Center (protocol number: 1056834), and Showa University (protocol number: 2383). A waiver of informed consent was granted based on the study’s retrospective nature. We reviewed the institutional databases to identify patients with ER-positive, HER2-negative, node-negative invasive breast cancer who had 21-gene signature assay data available and who had undergone definitive surgery between April, 2005 and May, 2018 and adjuvant endocrine therapy without any cytotoxic agents. We included only patients for whom archival FFPE tissue from definitive surgery was available. We excluded patients with pathological T4, pathological node-positive, distant metastatic disease, and male patients. Nodal micrometastasis was allowed. We included patients with RS of 11–25 according to TAILORx intermediate group.

Data collection

From the database, we extracted the 21-gene signature assay RS, age at diagnosis, menopausal status at diagnosis, histological type (ductal, lobular, or others), pathological T stage, progesterone receptor (PR) status, nuclear grade, and lymphovascular invasion status. ER and PR positivity were defined as tumors with > 1% of the cells positive using immunohistochemistry (IHC) staining. HER2 positivity was defined as a HER2/CEP17 fluorescence in situ hybridization ratio of ≥ 2.0 and/or an IHC staining score of 3+ [12]. At the MD Anderson Cancer Center, Breast Medical Oncology database (protocol number: 2004-0541) was used to identify the eligible patients.
Sample handling and processing

Archival FFPE tissues from either presurgical biopsy or resection specimens were prepared locally and sent to Sysmex Corporation (Kobe, Japan) under a Research Agreement.

The microarray mRNA expression data for 95 genes were used for 95-gene signature analysis. The list of probes set IDs is shown in Table S1. First, total RNA, including mRNA, was extracted from archival FFPE tissues using the RNeasy FFPE Kit (QIAGEN, Hilden, Germany). Next, second-strand cDNA was generated and amplified from the mRNA using the Ovation® FFPE WTA System (Tecan Genomics, Inc., Redwood City, CA) and then biotin labeled using the Encore® Biotin Module (Tecan Genomics, Inc., Redwood City, CA). We then hybridized to a GeneChip™ Human Genome U133 Plus 2.0 array (Thermo Fisher Scientific Inc., Waltham, MA) overnight (for 18 hours) according to the manufacturer’s protocol. Finally, the hybridized DNA microarray was fluorescence stained with GeneChip™ Fluorides Station 450Dx v.2 and scanned with the GeneChip™ Scanner 3000Dx v.2 (both from Thermo Fisher Scientific). For microarray analysis, the GeneChip Hybridization, Wash, and Stain Kit; GeneChip™ Hybridization Control Kit were used.

After obtaining the microarray data, quality control of data was performed using Expression Console™ software (Thermo Fisher Scientific). Only data satisfying the internal standards were subjected to 95-gene signature analysis. Using the 95-gene signature algorithm, a 95-gene signature score (about -0.1000 to 0.1000) was calculated from the expression levels of 95 genes on the microarray normalized by the ref-RMA method, and cases were classified into 95GC-H (> 0.0000) or 95GC-L (≤ 0.0000) groups. For details on the method of calculating the 95-gene signature score, refer to U.S. patent no. US20110263444A1.

Statistical analysis

Standard descriptive statistics and frequency tabulation were used to summarize data. The Chi-square test and Fisher’s exact test were used to evaluate the association between two categorical variables. The Kruskal–Wallis test was used to compare the distributions of continuous variables among different groups. Cox proportional hazards model was used to investigate the association between each variable and time to recurrence (TTR). TTR was defined as the time from surgery to invasive disease recurrence or breast cancer-specific death. Patients who had not experienced recurrence or death were censored at the time of last follow-up. A Kaplan–Meier estimate with a log rank test was used to compare TTR by group. Scatter plots were used to show the distribution of 95-gene signature and 21-gene signature assay scores. Pearson’s correlation coefficient was used to assess the association between 95-gene signature score and 21-gene signature assay score. All analyses were carried out using STATA 14 software (StataCorp, College Station, TX).

Results

Patient characteristics

A total of 229 patients were initially selected as meeting the inclusion criteria. Among them, total of 23 patients did not meet microarray quality control and were excluded, resulting in a total of 206 patients with RS of 11–25 for analysis. We classified 163 patients (79.1%) as 95GC-L; 43 patients (20.9%), as 95GC-H. There were no statistical differences in age, menopausal status, nuclear grade or PR status between the 95GC-H and 95GC-L groups (Table 1). The 95GC-H group had higher T stage tumors than did the 95GC-L group (P = 0.046).

Recurrence analysis

Median follow-up was 64.5 months. Among patients with RS of 11–25, TTR was significantly longer in the 95GC-L group than in the 95GC-H group (P < 0.001) (Fig. 1A). The univariate Cox proportional hazards model revealed that among patients with RS 11–25, 95GC-H was significantly associated with worse TTR than was 95GC-L (HR 5.94; 95%CI 1.81–19.53; P = 0.005) and no other factors are significantly associated with TTR (Table 2).

Next, we analyzed separate subgroups of patients aged ≤ 50 years and patients aged > 50 years. For patients with RS 11–25, only among patients with age > 50 years, the 95GC-H group had significantly shorter TTR than did the 95GC-L group (P = 0.004) (Fig. S1). The difference was not significant in patients aged ≤ 50 years (P = 0.09).

Correlation between 21-gene signature assay and 95-gene signature

The correlation between 21-gene signature assay and 95-gene signature scores is shown in Fig. 2. Among the 206 patients with RS of 11–25, the correlation coefficient (r) was 0.2 (Fig. 2). The distribution of scores for 95GC-H and 95GC-L was wide in both plots regardless of 21-gene signature assay score.
Table 1  Baseline patient characteristics for the 206 patients with RS 11–25

|                     | 95GC-L (N=163) n (%) | 95GC-H (N=43) n (%) | P-value |
|---------------------|----------------------|---------------------|---------|
| Age                 |                      |                     | 0.61    |
| ≤ 50 years          | 56 (34.4)            | 13 (30.2)           |         |
| > 50 years          | 107 (65.6)           | 30 (69.8)           |         |
| Menopausal status   |                      |                     | 0.93    |
| Premenopausal       | 58 (35.6)            | 15 (34.9)           |         |
| Postmenopausal      | 105 (64.4)           | 28 (65.1)           |         |
| T Stage             |                      |                     | 0.046   |
| T1                  | 122 (74.8)           | 24 (55.8)           |         |
| T2                  | 38 (23.3)            | 17 (39.5)           |         |
| T3                  | 2 (1.2)              | 1 (2.3)             |         |
| Unknown             | 1 (0.6)              | 1 (2.3)             |         |
| Histology           |                      |                     | 0.02    |
| Ductal              | 96 (58.9)            | 27 (62.8)           |         |
| Lobular             | 25 (15.3)            | 0 (0)               |         |
| Other               | 42 (25.8)            | 16 (37.2)           |         |
| Nuclear grade       |                      |                     | 0.07    |
| I                   | 64 (39.3)            | 13 (30.2)           |         |
| II                  | 84 (51.5)            | 21 (48.8)           |         |
| III                 | 14 (8.6)             | 9 (20.9)            |         |
| Unknown             | 1 (0.6)              | 0 (0)               |         |
| PR status           |                      |                     | 0.79    |
| Negative            | 17 (10.4)            | 5 (11.6)            |         |
| Positive            | 146 (89.6)           | 38 (88.4)           |         |
| RS, median (range)  | 19 (11–25)           | 20 (15–25)          | 0.1     |

PR progesterone receptor, RS Oncotype DX® Recurrence Score

Table 2  Cox regression analysis for TTR for the 206 patients with RS 11–25

|                     | HR (95%CI) | P-value |
|---------------------|------------|---------|
| Age                 |            |         |
| ≤ 50 years          | Reference  | 0.37    |
| > 50 years          | 1.92 (0.42–8.81) | 0.38    |
| Menopausal status   |            |         |
| Premenopausal       | Reference  | 0.38    |
| Postmenopausal      | 1.89 (0.41–8.72) | 0.38    |
| T Stage             |            |         |
| T1                  | Reference  | 0.16    |
| T2 and T3           | 2.36 (0.74–7.5) | 0.72    |
| Histology           |            |         |
| Ductal              | Reference  | 0.72    |
| Lobular             | 1.63 (0.34–7.87) | 0.13    |
| Other               | 1.63 (0.42–6.34) | 0.13    |
| Nuclear grade       |            |         |
| I                   | Reference  | 0.13    |
| II                  | 5.34 (0.68–42.7) | 0.87    |
| III                 | 5.0 (0.45–55.3) | 0.87    |
| PR status           |            |         |
| Negative            | Reference  | 0.005   |
| Positive            | 1.18 (0.15–9.14) | 0.005   |
| 95GC classification  |            |         |
| Low                 | Reference  | 0.005   |
| High                | 5.94 (1.81–19.53) | 0.005   |

PR progesterone receptor, 95GC Curebest™ 95GC Breast

Fig. 1  Time to recurrence (TTR) analysis. TTR curve for patients with tumors classified as 95GC-L and as 95GC-H for populations with “intermediate” 21-gene signature assay RS (11–25)

Fig. 2  Correlation between 95GC and 21-gene signature assay scores. Scatterplot representing scores for each patient with RS of 11–25. Orange dots represent a patient with recurrence
Discussion

In this study, we demonstrated that 95-gene signature can stratify patients with ER-positive, HER2-negative, node-negative invasive breast cancer and intermediate RS of 11–25 into two risk categories, low and high, in terms of TTR. We also showed lack of a strong correlation between 95-gene signature score and 21-gene signature assay score, which might suggest that 95-gene signature reflects biological characteristics differing from what 21-gene signature shows.

Among patients with intermediate RS of 11–25, the score range used in the TAILORx trial, the risk of recurrence in the 95GC-H group was significantly high compared to that of the 95GC-L group (HR 5.94; 95%CI 1.81–19.53; \( P = 0.005 \)) [6]. None of the other clinico-pathological factors analyzed were associated with TTR. Interestingly, the correlation between individual 95-gene signature and 21-gene signature assay scores was not strong (Fig. 2). The 95-gene signature classifier assesses 95 genes totally exclusive of the genes used to create the 21-gene signature assay RS, and this weak correlation suggests that the ability of 95-gene signature is biologically independent of that of 21-gene signature assay [8].

An initial study of the 95-gene signature showed its prognostic utility in ER-positive, node-negative breast cancer [8]. A follow-up study of 459 patients consisting of a cohort of 148 patients from a university hospital in Japan and a cohort of 311 patients from public databases (GSE17705, GSE12093) tested the prognostic ability of 95-gene signature in patients with ER-positive, node-negative breast cancer and intermediate estimated RS of 18–30 based on the Recurrence Online 21-gene classifier [11]. The 95GC-L group had a significantly better RFS rate than did the 95GC-H group (\( P = 0.002 \)). This is the first study to investigate 95-gene signature in the context of actual 21-gene signature assay.

The TAILORx trial demonstrated that endocrine and chemoendocrine therapy did not significantly differ in terms of invasive disease-free survival in patients with hormone receptor-positive, HER2-negative, node-negative breast cancer and RS of 11–25 (HR [endocrine vs. chemoendocrine therapy], 1.08; 95% CI 0.94–1.24; \( P = 0.26 \)) [6]. In that study, the estimated invasive disease-free survival rate at 9 years in patients with RS of 11–25 treated with endocrine therapy was 83.3% ± 0.9%; thus, approximately 17% of intermediate RS patients may have an event within 9 years and could potentially have a survival benefit from adjuvant chemotherapy. Certain aspects of the TAILORx trial should be noted. First, the median tumor size in the study was 1.5 cm (T1), and the high proportion of relatively small tumors might have affected the results. There might not have been significant survival benefit from additional chemotherapy in part because of a favorable baseline characteristics seen among patients with T1 tumors. In contrast, among our study cohort with intermediate defined as RS 11–25, 28% of patients had non-T1 disease (T2, 55; T3, 3), which might have led to a significant difference in survival between the 95GC-H and 95GC-L groups.

Our findings suggest that 95-gene signature is associated with the risk of recurrence in patients with intermediate RS. Another notable finding of our study was that 95-gene signature successfully divided patients aged >50 years into high- and low-risk groups. The TAILORx trial did not have power enough to prove whether aged >50 years had a survival benefit from chemoendocrine therapy; however, using the 95-gene signature, it may be possible to identify a population who would have a benefit. There is also a study showing that 95GC-H group had a significantly higher partial response rate after neoadjuvant chemotherapy than 95GC-L group (\( P = 0.003 \)). This result might support the potential capability to predict response to chemotherapy [13]. The 95-gene signature classification was not significant among patients aged ≤50 years, which may be attributable to the small sample size of that population. Recently, Sparano et al. showed that a new tool (RSCline), which integrates the 21-gene recurrence score and the clinico-pathological features of histologic tumor grade, tumor size, and patient age at surgery, could provide more individualized estimation of survival benefit from adding adjuvant chemotherapy to endocrine therapy [14].

There are several limitations of this study. First, this is a retrospective study, and the ability of 95-gene signature to identify patients with intermediate RS who can benefit from adjuvant chemoendocrine therapy is still unknown. Second, our follow-up period was relatively short compared with that of the TAILORx trial; further study is needed. Third, subgroup analysis particularly by age was not fully performed because of the limited number of events in each subgroup. Fourth, although all of the clinicians followed clinical practice guidelines, each treating physician decided on the entire treatment plans, and we do not have information about type of surgery, radiation therapy, or adjuvant systemic therapy, which could have affected the final results. Fifth, we included patients with node-negative disease, and the recent presentation about the RxPONDER trial at the 2020 San Antonio Breast Cancer Symposium led us to decide that testing the 95GC in patients with node-positive breast cancer was necessary [15].

Conclusions

Our results support that the 95-gene signature stratifies patients with ER-positive, HER2-negative, node-negative invasive breast cancer and intermediate RS of 11–25 into...
high and low groups that are associated with recurrence risk of invasive disease. Further retrospective analysis in the prospectively accrued TAILORx population is warranted to confirm that 95-gene signature can identify patients who would benefit from adjuvant chemotherapy.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10549-021-06276-7.

Acknowledgements Editorial assistance was provided by Sunita Patterson and Donald R Norwood of Scientific Publication Services, Research Medical Library, The University of Texas MD Anderson Cancer Center. We also thank Kirk Y. Hirata and Christine Nakamoto of Pathology, The Queen’s Medical Center for collection archival tissue samples.

Funding This work was supported by the Morgan Welch Inflammatory Breast Cancer Research Program; a Grant from the State of Texas Rare and Aggressive Breast Cancer Research Program; the MD Anderson Breast Cancer Research Program; a Grant from the State of Texas MD Anderson Cancer Center Support Grant from the National Cancer Institute (CA016672).

Declarations Conflict of interest K.Y., T.M., and S.T. are employees of Sysmex Corporation (Curebest™ 95GC Breast service provider), Y.N. holds a joint patent on Curebest™ 95GC Breast with Sysmex Corporation, receive research funds from Sysmex and AstraZeneca, and received a lecture fee of 100,000 yen a year from Sysmex Corporation, AstraZeneca and Takeda. S.N. has received honoraria and research grants from Sysmex Corporation and has been an advisor for Sysmex Corporation and holds a joint patent on Curebest™ 95GC Breast with Sysmex. N.T.U. has research grants with Sysmex Corporation and with Genomic Health.

Ethical approval This retrospective chart review with linked tissue analysis was approved by the central Institutional Review Boards at the five participating institutions in the USA and Japan: The University of Texas MD Anderson Cancer Center (protocol number: PA15-0905), University of Hawai‘i Cancer Center (protocol number: RA-2017-021), Medical College of Wisconsin (protocol number: PRO00029366), Anne Arundel Medical Center (protocol number: 1056834), and Showa University (protocol number: 2383). A waiver of informed consent was granted based on the study’s retrospective nature.

Informed consent For this type of study, formal consent is not required.

References

1. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. https://doi.org/10.1056/NEJMoa041588

2. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 25(33):5287–5312. https://doi.org/10.1200/jco.2007.14.2364

3. National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology: breast cancer. V2.2015. Available at http://www.nccn.org/professionals/physician_gls/f_guide lines.asp

4. Aebi S, Davidson T, Gruber G, Castiglione M (2010) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol/ ESMO 21(Suppl 5):v9–14. https://doi.org/10.1093/annonc/ mdq159

5. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albin KS, Hayes DF, Geyer CE, Dees EC, Perez EA, Olson JA, Zajewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood PC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Bruksky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373(21):2005–2014. https://doi.org/10.1056/NEJMoa1510764

6. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albin KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Bruksky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111–121. https://doi.org/10.1056/NEJMoa1804710

7. Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albin KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Bruksky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW (2019) Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 380(25):2395–2405. https://doi.org/10.1056/NEJMoa1904819

8. Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S (2011) Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients. Breast Cancer Res Treat 128(3):633–641. https://doi.org/10.1007/s10549-010-1145-z

9. Shino S, Kinoshita T, Aogi K, Ohsumi S, Takahashi M, Ito K-I, Oba T, Arihiro K, Shiroma N, Tsukamoto F, Yoshida M (2017) 185PThe first report of multicenter validation study of 95-gene classifier, a multi-gene prognostic assay of estrogen receptor positive and node negative breast cancer patients. Ann Oncol 28(Suppl 5):v56. https://doi.org/10.1093/annonc/mdx362.035

10. Gyoryf B, Benke Z, Lancyzyk A, Balazs B, Szallasi Z, Timar J, Schafer R (2012) RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat 132(3):1025–1034. https://doi.org/10.1007/s10549-011-1676-y

11. Naoi Y, Kishi K, Tsunashima R, Shimazu K, Shimomura A, Maruyama N, Shimoda M, Kagara N, Baba Y, Kim SJ, Noguchi S (2013) Comparison of efficacy of 95-gene and 21-gene classifier (Oncomtype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients. Breast Cancer Res Treat 140(2):299–306. https://doi.org/10.1007/s10549-013-2640-9

12. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allred DC, Bliss JM, Chen CA, Coates AS, Cronin M, Delaloge S, Hagemann I, Hortobagyi GN, Irwin M, Jones SE, Katarzynko K, Kaufmann M, Karlamangalid G, Krop ET, Labianca R, Llach P, Smith IE, Testa M, Thompson I, Viale G, Berenberg JL, Abrams J, Sledge GW (2018) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111–121. https://doi.org/10.1056/NEJMoa1804710
13. Tsunashima R, Naoi Y, Kishi K, Baba Y, Shimomura A, Maruyama N, Nakayama T, Shimazu K, Kim SJ, Tamaki Y, Noguchi S (2012) Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy. Cancer Lett 324(1):42–47. https://doi.org/10.1016/j.canlet.2012.04.017

14. Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S (2021) Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer. J Clin Oncol 39(6):557–564. https://doi.org/10.1200/jco.20.03007

15. Kalinsky K, Barlow WE, Meric-Bernstam F, Gralow JR, Albain KS, Hayes D, Lin N, Perez EA, Goldstein LJ, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Gil MG, Arce-Salinas C, Brain E, Park IH, Pierga J-Y, Lluch AH, Vasquez MR, Borrego MR, Jung KH, Ferrero J-M, Schott A, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Hortobagyi G, Pusztai L (2021) Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder). Cancer Res. https://doi.org/10.1158/1538-7445.Sabcs20-gs3-00

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Takeo Fujii1,2,3,4 · Hiroko Masuda5 · Yee Chung Cheng6 · Fei Yang7 · Aysegul A. Sahin8 · Yasuto Naoi9 · Yuki Matsunaga5 · Akshara Raghavendra1 · Arup Kumar Sinha3 · Jose Rodrigo Espinosa Fernandez1 · Anjali James1 · Keisuke Yamagishi10 · Tomoko Matsushima10 · Robert Schuetz4 · Debu Tripathy1 · Sachiy0 Tada10 · Rubie S. Jackson11 · Shinzaburo Noguchi9,12 · Seigo Nakamura5 · Jared D. Acoba3,4 · Naoto T. Ueno1,2

1 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
2 Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
3 John A. Burns School of Medicine, University of Hawai‘i, 651 Ilalo St, Honolulu, HI 96813, USA
4 University of Hawai‘i Cancer Center, 701 Ilalo St, Honolulu, HI 96813, USA
5 Department of Breast Surgical Oncology, Showa University, 1-5-8 Hatanodai Shinagawa-ku, Tokyo 142-8666, Japan
6 Division of Hematology and Oncology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226, USA
7 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
8 Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
9 Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita-shi, Osaka 565-0871, Japan
10 Sysmex Corporation, 1-5-1, Wakinohama-kaigandori, Chuo-ku, Kobe, Hyogo 651-0073, Japan
11 Anne Arundel Medical Center, Rebecca Fortney Breast Center, 2000 Medical Pkwy, Annapolis, MD 21401, USA
12 Hyogo Prefectural Nishinomiya Hospital, 13-9, Rokutanjicho, Nishinomiya, Hyogo 662-0918, Japan